Abbott Laboratories said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan Inc.
Continue Reading Below
Abbott on Wednesday said sales from continuing and discontinued operations rose 4.7 percent to $5.6 billion in the third quarter. That included generic medicines, now considered discontinued products, which will be sold to Mylan.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)